<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103519</url>
  </required_header>
  <id_info>
    <org_study_id>DIT-803</org_study_id>
    <nct_id>NCT00103519</nct_id>
  </id_info>
  <brief_title>Study of DITPA in Patients With Congestive Heart Failure</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Titan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Titan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of DITPA relative to placebo in patients with&#xD;
      New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low&#xD;
      serum T3. DITPA is an investigational agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Congestive heart failure (CHF) is a major public health problem associated with&#xD;
      significant morbidity and mortality in patients with New York Heart Association (NYHA) class&#xD;
      III or IV disease. Multiple studies have identified a particularly high-risk group of&#xD;
      patients who have reduced thyroid hormone activity, specifically, low serum triiodothyronine&#xD;
      (T3) levels. This group represents approximately 30% of patients with NYHA class III or IV&#xD;
      disease and has significantly higher mortality rates than those with normal T3.&#xD;
&#xD;
      DITPA (3,5-diiodothyropropionic acid) is an analogue of naturally occurring thyroid hormone&#xD;
      (T3) that has been specifically designed to improve cardiac performance with a lower&#xD;
      potential for tachycardia in CHF patients. Although structurally similar to T3, DITPA has a&#xD;
      propionic acid side chain and lacks an iodine at the 3' position of the outer phenolic ring.&#xD;
      While DITPA binds to the same thyroid hormone receptors as T3, binding affinities are&#xD;
      significantly less, suggesting partial agonistic actions. Preclinical studies with DITPA have&#xD;
      supported a rationale for its use in patients with CHF.&#xD;
&#xD;
      Primary objective: To assess the safety and tolerability of DITPA in patients with NYHA class&#xD;
      III/IV CHF and low serum T3.&#xD;
&#xD;
      Secondary Objective: To obtain preliminary evidence of the efficacy of DITPA in patients with&#xD;
      NYHA class III/IV CHF and low serum T3&#xD;
&#xD;
      Design: The multi-center, randomized, double-blind, placebo-controlled study is designed to&#xD;
      evaluate the safety and tolerability of DITPA in patients with NYHA class III or IV CHF who&#xD;
      have low levels of serum T3 with normal levels of thyroid stimulating hormone (TSH).&#xD;
&#xD;
      One hundred and fifty patients at approximately 35 centers in the U.S. will be randomized to&#xD;
      1 of 3 treatment groups in a 1:1:1 ratio (i.e., 50 patients per treatment group):&#xD;
&#xD;
        -  DITPA at 180 mg/day (90 mg twice a day [BID], orally)&#xD;
&#xD;
        -  DITPA at 360 mg/day (180 mg BID, orally)&#xD;
&#xD;
        -  Placebo BID, orally&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated for reasons unrelated to safety or efficacy.&#xD;
  </why_stopped>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of DITPA</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of DITPA</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>DITPA 180 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DITPA 180 mg/day BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DITPA 360 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DITPA 360 mg/day BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DITPA (3,5-diiodothyropropionic acid)</intervention_name>
    <arm_group_label>DITPA 180 mg/day</arm_group_label>
    <arm_group_label>DITPA 360 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than or equal to 18 years of age&#xD;
&#xD;
          -  NYHA class III or IV CHF&#xD;
&#xD;
          -  Females must not be pregnant or lactating. Females of childbearing potential and males&#xD;
             must use a reliable means of contraception&#xD;
&#xD;
          -  Serum total T3 &lt;= 95 ng/dL with normal levels of TSH&#xD;
&#xD;
          -  On a regimen consisting of angiotensin-converting enzyme inhibitors and/or angiotensin&#xD;
             receptor antagonists, beta blockers, and diuretics for a minimum of 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Clinically stable for 2 weeks prior to randomization (defined as no change in&#xD;
             functional class by NYHA, no hospitalization or ER visit, and no intravenous inotropic&#xD;
             or vasodilator treatment for 2 weeks)&#xD;
&#xD;
          -  An LVEF &lt;= 40%, documented within 6 months prior to randomization, or &gt; 6 months with&#xD;
             confirmation of LVEF by local echocardiographic measurements within 2 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New onset CHF (less than 3 months prior to randomization)&#xD;
&#xD;
          -  Active myocarditis, hypertrophic cardiomyopathy, uncorrected primary valvular disease,&#xD;
             restrictive cardiomyopathy, uncorrected congenital heart disease, or constrictive&#xD;
             pericarditis&#xD;
&#xD;
          -  Myocardial infarction, unstable ischemic heart disease, stroke, or coronary&#xD;
             revascularization procedure within 4 weeks prior to randomization; or an expectation&#xD;
             of a coronary revascularization procedure, cardiac transplant, or left ventricular&#xD;
             assist device placement being needed within 24 weeks after randomization&#xD;
&#xD;
          -  History of sudden arrhythmic syncope or sustained ventricular arrhythmia, unless the&#xD;
             patient has an implantable cardioverter defibrillator (ICD) for at least 12 weeks&#xD;
             prior to randomization; history of clinically significant heart block, unless the&#xD;
             patient has had a pacemaker at least 12 weeks prior to randomization&#xD;
&#xD;
          -  History of cardiac resynchronization therapy in the last 12 weeks prior to&#xD;
             randomization or expectation of cardiac resynchronization therapy or ventricular&#xD;
             mechanical assistance needed within 24 weeks after randomization&#xD;
&#xD;
          -  History of cardiac transplant&#xD;
&#xD;
          -  Heart rate &lt; 50 beats per minute or &gt; 130 beats per minute&#xD;
&#xD;
          -  Systolic blood pressure &lt;= 80 mm Hg&#xD;
&#xD;
          -  Serum creatinine =&gt; 2.5 mg/dL&#xD;
&#xD;
          -  Treatment with intravenous vasodilators (including nesiritide) or inotropes within 2&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Receipt of any other investigational agent or device within 4 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Diagnosis of other non-cardiac underlying medical conditions expected to impact their&#xD;
             mortality within 24 weeks after randomization&#xD;
&#xD;
          -  Drug or alcohol dependence, or other conditions which may affect study compliance&#xD;
&#xD;
          -  History of thyroid disorders of any form within 24 weeks prior to randomization&#xD;
&#xD;
          -  Use of thyroid supplements (levothyroxine, liothyronine, etc.) or any preparation&#xD;
             containing thyromimetic agents within 24 weeks prior to randomization&#xD;
&#xD;
          -  Supraventricular arrhythmia refractory to conventional treatment, as judged by the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milton Packer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Heart Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Solutions</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Sarver Heart Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants Medical Group</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Research Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clevaland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center Heart Place</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William S. Middleton Memorial Veterans Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>February 9, 2005</study_first_submitted>
  <study_first_submitted_qc>February 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2005</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, DITPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,5-diiodothyropropionic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

